Table 4.
Second solid cancers (left) and second hematological malignancies (right) observed during the follow-up period.
| Solid cancers | n = 49 | Hematological malignancies | n = 19 |
|---|---|---|---|
| Prostate | 11 | MGUS/MGCS | 6 |
| Nonmelanoma skin cancer | 11 | MDS | 4 |
| Lung | 7 | NHLa | 3 |
| Colorectal | 7 | MDS/MPN | 2 |
| Kidney | 4 | MPN | 1 |
| Pancreas | 2 | AML | 1 |
| Esophagus | 1 | MM | 1 |
| Pleural | 1 | CLL | 1 |
| Unknown | 1 | ||
| Kaposi | 1 | ||
| Biliary tract | 1 | ||
| Bladder | 1 | ||
| Breast | 1 |
a1 DLBCL, 1 FL, 1 SMZL.
AML acute myeloid leukemia, MM multiple myeloma, CLL chronic lymphocytic leukemia, NHL non-Hodgkin’s lymphoma, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, SMZL splenic marginal zone lymphoma.